TY  - GEN
AU  - Pasello,Giulia
AU  - Vicario,Giovanni
AU  - Zustovich,Fable
AU  - Oniga,Francesco
AU  - Gori,Stefania
AU  - Rosetti,Francesco
AU  - Bonetti,Andrea
AU  - Favaretto,Adolfo
AU  - Toso,Silvia
AU  - Redelotti,Roberta
AU  - Santo,Antonio
AU  - Bernardi,Daniele
AU  - Giovanis,Petros
AU  - Oliani,Cristina
AU  - Calvetti,Lorenzo
AU  - Gatti,Carlo
AU  - Palazzolo,Giovanni
AU  - Baretta,Zora
AU  - Bortolami,Alberto
AU  - Bonanno,Laura
AU  - Basso,Marco
AU  - Menis,Jessica
AU  - Corte,Donatella Da
AU  - Frega,Stefano
AU  - Guarneri,Valentina
AU  - Conte,PierFranco
TI  - From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for 
SN  - 1549-490X
PY  - 2020///0720
KW  - Adult
KW  - Afatinib
KW  - economics
KW  - Aged
KW  - Aged, 80 and over
KW  - Carcinoma, Non-Small-Cell Lung
KW  - diagnosis
KW  - Cost-Benefit Analysis
KW  - Critical Pathways
KW  - standards
KW  - DNA Mutational Analysis
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - ErbB Receptors
KW  - antagonists & inhibitors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Follow-Up Studies
KW  - Gefitinib
KW  - Guideline Adherence
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Practice Guidelines as Topic
KW  - Progression-Free Survival
KW  - Prospective Studies
KW  - Protein Kinase Inhibitors
KW  - Time Factors
KW  - Treatment Failure
KW  - Assessment of Medication Adherence
N1  - Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1634/theoncologist.2018-0712
ER  -